MX375548B - Manufactura de neurotoxinas de clostridium botulinum recombinantes. - Google Patents

Manufactura de neurotoxinas de clostridium botulinum recombinantes.

Info

Publication number
MX375548B
MX375548B MX2016013803A MX2016013803A MX375548B MX 375548 B MX375548 B MX 375548B MX 2016013803 A MX2016013803 A MX 2016013803A MX 2016013803 A MX2016013803 A MX 2016013803A MX 375548 B MX375548 B MX 375548B
Authority
MX
Mexico
Prior art keywords
manufacture
clostridium botulinum
botulinum neurotoxins
recombinant clostridium
recombinant
Prior art date
Application number
MX2016013803A
Other languages
English (en)
Other versions
MX2016013803A (es
Inventor
Gavin Stephen Hackett
Sai Man Liu
Shilpa Palan
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of MX2016013803A publication Critical patent/MX2016013803A/es
Publication of MX375548B publication Critical patent/MX375548B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

La presente invención proporciona métodos para producir una proteína de BoNT/A de di-cadena soluble.
MX2016013803A 2014-04-29 2015-04-29 Manufactura de neurotoxinas de clostridium botulinum recombinantes. MX375548B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1407525.3A GB201407525D0 (en) 2014-04-29 2014-04-29 Manufacture of recombinant clostridium botulinum neurotoxins
PCT/GB2015/051250 WO2015166242A1 (en) 2014-04-29 2015-04-29 Manufacture of recombinant clostridium botulinum neurotoxins

Publications (2)

Publication Number Publication Date
MX2016013803A MX2016013803A (es) 2017-03-09
MX375548B true MX375548B (es) 2025-03-06

Family

ID=50972048

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013803A MX375548B (es) 2014-04-29 2015-04-29 Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX2020010262A MX2020010262A (es) 2014-04-29 2016-10-20 Manufactura de neurotoxinas de clostridium botulinum recombinantes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010262A MX2020010262A (es) 2014-04-29 2016-10-20 Manufactura de neurotoxinas de clostridium botulinum recombinantes.

Country Status (19)

Country Link
US (3) US10307468B2 (es)
EP (3) EP4309668A3 (es)
JP (2) JP6656171B2 (es)
KR (3) KR102593951B1 (es)
CN (1) CN106414759B (es)
AU (3) AU2015255068B2 (es)
CA (1) CA2941160A1 (es)
DK (1) DK3137621T3 (es)
EA (1) EA201692188A1 (es)
ES (2) ES2974567T3 (es)
GB (1) GB201407525D0 (es)
HU (1) HUE045564T2 (es)
MX (2) MX375548B (es)
PL (1) PL3137621T3 (es)
PT (1) PT3137621T (es)
SA (2) SA520412669B1 (es)
SG (1) SG11201607400VA (es)
UA (1) UA129511C2 (es)
WO (1) WO2015166242A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
SG177357A1 (en) * 2009-06-25 2012-02-28 Revance Therapeutics Inc Albumin-free botulinum toxin formulations
HRP20181869T1 (hr) * 2009-10-21 2019-01-11 Revance Therapeutics, Inc. Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CA2880897C (en) * 2012-11-21 2020-01-14 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
EA201890587A1 (ru) 2015-08-27 2018-09-28 Президент Энд Феллоуз Оф Гарвард Колледж Композиции и способы для лечения боли
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PT3463432T (pt) * 2016-05-27 2021-01-12 Ipsen Biopharm Ltd Formulação líquida de neurotoxina estabilizada com triptofano ou tirosina
IL308091B1 (en) 2016-09-13 2026-01-01 Allergan Inc Protein-free stabilized Clostridium toxin preparations
EP3694540B1 (en) * 2017-10-13 2024-11-20 Wisconsin Alumni Research Foundation Botulinum neurotoxin a subtype 6 and pharmacological methods of use
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
KR102516203B1 (ko) * 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 제조방법
KR102516204B1 (ko) 2019-04-15 2023-03-30 (주)제테마 보툴리눔 독소의 정제방법
KR20220154738A (ko) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法
CA3231083A1 (en) 2021-09-16 2023-03-23 Nicolae GRIGORE Modified bont/a for use in the treatment of cervical dystonia
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
KR20240067100A (ko) 2021-09-23 2024-05-16 입센 바이오팜 리미티드 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a
CN118126144B (zh) * 2024-03-14 2026-01-16 河北平朴生物科技合伙企业(有限合伙) 一种a型重组肉毒素的纯化方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005222A1 (en) * 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
DE19856897A1 (de) 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
JP2004512004A (ja) * 1999-05-12 2004-04-22 ユナイテッド　ステイツ　アーミー　メディカル　リサーチ　アンド　マテリエル　シーエムディー ボツリヌス神経毒に対する組換えワクチン
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
AU2005327458B2 (en) * 2005-03-03 2011-12-15 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
EP2377881B1 (en) * 2005-09-19 2017-04-26 Allergan, Inc. Clostridial toxin activatable clostridial toxins
CN101175478A (zh) * 2005-10-06 2008-05-07 阿勒根公司 非蛋白稳定的梭菌毒素药物组合物
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
HRP20181869T1 (hr) * 2009-10-21 2019-01-11 Revance Therapeutics, Inc. Metode i sustavi za pročišćavanje nekompleksiranog botulinskog neurotoksina
IN2012DN01954A (es) * 2009-10-21 2015-08-21 Merz Pharma Gmbh & Co Kgaa
DK2677029T3 (da) * 2011-05-19 2017-08-07 Ipsen Bioinnovation Ltd Fremgangsmåder til fremstilling af proteolytisk bearbejdede polypeptider
CA2880897C (en) * 2012-11-21 2020-01-14 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
DK3137621T3 (da) 2019-09-30
EP3591065B1 (en) 2024-01-10
EP4309668A3 (en) 2024-07-10
US20230285521A1 (en) 2023-09-14
ES2749049T3 (es) 2020-03-18
SA516380060B1 (ar) 2021-03-07
PT3137621T (pt) 2019-10-29
MX2016013803A (es) 2017-03-09
US10307468B2 (en) 2019-06-04
WO2015166242A1 (en) 2015-11-05
EP3591065A1 (en) 2020-01-08
JP6994523B2 (ja) 2022-02-04
EA201692188A1 (ru) 2017-03-31
KR102770326B1 (ko) 2025-02-20
ES2974567T3 (es) 2024-06-27
KR20250026403A (ko) 2025-02-25
GB201407525D0 (en) 2014-06-11
KR20230152778A (ko) 2023-11-03
CA2941160A1 (en) 2015-11-05
SA520412669B1 (ar) 2022-08-02
JP2017514486A (ja) 2017-06-08
KR102593951B1 (ko) 2023-10-26
MX2020010262A (es) 2020-10-28
US20180117128A1 (en) 2018-05-03
AU2021261858A1 (en) 2021-12-02
AU2015255068A1 (en) 2016-10-20
AU2019219761B2 (en) 2021-08-05
CN106414759A (zh) 2017-02-15
AU2015255068B2 (en) 2019-05-23
BR112016022025A2 (pt) 2017-10-31
SG11201607400VA (en) 2016-11-29
EP4309668A2 (en) 2024-01-24
PL3137621T3 (pl) 2020-03-31
US20190201505A1 (en) 2019-07-04
US11642399B2 (en) 2023-05-09
CN106414759B (zh) 2021-05-28
JP6656171B2 (ja) 2020-03-04
AU2021261858B2 (en) 2025-03-06
JP2020090523A (ja) 2020-06-11
AU2019219761A1 (en) 2019-09-05
EP3137621A1 (en) 2017-03-08
KR20160147918A (ko) 2016-12-23
UA129511C2 (uk) 2025-05-21
HUE045564T2 (hu) 2019-12-30
EP3137621B1 (en) 2019-07-17

Similar Documents

Publication Publication Date Title
MX375548B (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
IL263058A (en) Engineered botulinum neurotoxins
PH12017501365B1 (en) Novel promoter and uses thereof
EP3009505A4 (en) Recombinant strain producing l-amino acids, constructing method therefor and method for producing l-amino acids.
PT3274364T (pt) Neurotoxina botulínica manipulada
NZ725568A (en) Modified j-chain
EP3230457A4 (en) Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
EP3615669A4 (en) BOTULINIC NEUROTOXINS PRODUCTION PROCESSES
MX2018015697A (es) Composición de alimentación que comprende una proteasa ácida.
PH12017501678A1 (en) Recombinant microorganism for improved production of finie chemicals
MX2024000004A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
MX2016014227A (es) Estabilizante para procesos de produccion de poliol polimerico.
MX2016014296A (es) Proceso para preparar un poliol polimerico.
MX2020007742A (es) Procesos para preparar fluorocetolidos.
SG11201704625UA (en) Novel methods for enzyme mediated polypeptide conjugation using sortase
IL264109A (en) Production of colostridal activated neurotoxins
EP3221448A4 (en) Process for producing recombinant trypsin
HK40006144A (en) Engineered botulinum neurotoxins
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
EP3221449A4 (en) Process for refolding recombinant chymotrypsin
BR112018012851A2 (pt) cepas de expressão de proteína melhoradas
HK40007773A (zh) 活化的梭菌神经毒素的生产
AU361517S (en) Tyres for automobiles (DX10 A/T)
GB201603516D0 (en) Hydrocarbon production technology(c) H.P.T.(C)
TH1601000492A (th) วิธีการสำหรับการผลิตพอลิคาร์บอเนต ไดออล, พอลิคาร์บอเนต ไดออล, วิธีการสำหรับการผลิตพอลิยูรีเธนและพอลิยูรีเธน

Legal Events

Date Code Title Description
FG Grant or registration